Mycobacterium haemophilum infection in an SLE patient on mycophenolate mofetil

We describe a case of Mycobacterium haemophilum in an immunocompromised patient with systemic lupus erythematosus (SLE). Mycobacterium haemophilum is a recently described pathogen which has not been previously described either in SLE patients or patients on Mycophenolate Mofetil. Mycobacterium haemo...

Full description

Saved in:
Bibliographic Details
Published in:Lupus 2002-01, Vol.11 (4), p.249-252
Main Authors: Teh, C L, Kong, K O, Chong, A Py, Badsha, H
Format: Article
Language:English
Subjects:
Adult
Anti-Bacterial Agents - therapeutic use
Antirheumatic Agents - therapeutic use
Clarithromycin - therapeutic use
Cyclophosphamide - therapeutic use
Ethambutol - therapeutic use
Female
Humans
Immunosuppressive Agents - adverse effects
Immunosuppressive Agents - therapeutic use
Isoniazid - therapeutic use
Leg - microbiology
Leg - pathology
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - drug therapy
Lupus Erythematosus, Systemic - microbiology
Muscle, Skeletal - microbiology
Muscle, Skeletal - pathology
Mycobacterium haemophilum
Mycobacterium Infections - complications
Mycobacterium Infections - microbiology
Mycophenolic Acid - adverse effects
Mycophenolic Acid - analogs & derivatives
Mycophenolic Acid - therapeutic use
Rifampin - therapeutic use
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We describe a case of Mycobacterium haemophilum in an immunocompromised patient with systemic lupus erythematosus (SLE). Mycobacterium haemophilum is a recently described pathogen which has not been previously described either in SLE patients or patients on Mycophenolate Mofetil. Mycobacterium haemophilum can be difficult to diagnose, as it may not have the granulomas characteristic of atypical mycobacterial infections. Combination therapy with at least two drugs for several months is required and the outcome depends on the patient's underlying immunocompromised state. Our report highlights the need for early diagnosis and treatment of Mycobacterium haemophilum in immunocompromised patients with SLE.
ISSN:0961-2033
1477-0962
DOI:10.1191/0961203302lu175cr